From Medscape Oncology

Coverage From The

European Hematology Association (EHA) 2019 Annual Meeting

June 13 - 16, 2019; Amsterdam, The Netherlands

June 13 - 16, 2019 Amsterdam, The Netherlands

Conference News

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News from EHA 2018

  • Vitamin D Deficiency and Reduced Hodgkin Lymphoma Survival Vitamin D Deficiency and Reduced Hodgkin Lymphoma Survival A large study has found that patients with Hodgkin lymphoma who showed baseline deficiencies in vitamin D had significantly shorter progression-free and overall survival.
  • New Drug for PHN Taken Only Once Every 8 Weeks New Drug for PHN Taken Only Once Every 8 Weeks Ravulizumab, a new drug for paroxysmal nocturnal hemoglobinuria (PNH), requires IV infusion only once every 8 weeks, compared with every 2 weeks for eculizumab, the only drug currently approved for this disorder.
  • Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma A novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the standard combination of rituximab and chemotherapy in the RELEVANCE trial.

Previous Coverage